Roche’s novel checkpoint inhibitor delivers mixed results in new lung cancer study

feature-image

Play all audios:

Loading...

Roche on Wednesday said a two-drug combination that includes a novel but still experimental checkpoint-blocking immunotherapy significantly delayed tumor progression in a mid-stage study of


non-small cell lung cancer patients.


Reaction to the results might be muted, however, because the new combination treatment — tiragolumab plus Tecentriq — only showed a meaningful benefit in a subset of lung cancer patients.


That profile makes it unlikely to compete against Merck’s dominant Keytruda-chemotherapy combination.


Roche announced the full study results to coincide with the release of a research abstract for the annual meeting of the American Society of Clinical Oncology (ASCO).